Long term management of obstructive sleep apnea and its comorbidities
Palabras clave : 
Obstructive sleep apnea
Cardiovascular disease
Hypertension
Diabetes
Dislipemia
Long-term management
Outcomes
Fecha de publicación : 
2019
Editorial : 
PAGEPress Publications
ISSN : 
2049-6958
Nota: 
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cita: 
Marin-Oto, M. (Marta); Vicente, E.E. (Eugenio E.); Marin, J.M. (José M.). "Long term management of obstructive sleep apnea and its comorbidities". Multidisciplinary Respiratory Medicine. 14, 2019, 21
Resumen
Obstructive sleep apnea (OSA) is a worldwide highly prevalent disease associated with systemic consequences, including excessive sleepiness, impairment of neurocognitive function and daytime performance, including driving ability. The long-term sequelae of OSA include and increase risk for cardiovascular, cerebrovascular and metabolic syndrome disorders that ultimately lead to premature death if untreated. To ensure optimal long-term outcomes, the assessment and management of OSA should be personalized with the involvement of the appropriate specialist. Most studies have demonstrated inmediate improvement in daytime somnolence and quality of life with CPAP and other therapies, but the effect of long-term treatment on mortality is still under debate. Currently, the long-term management of OSA should be based on a) identifying physiological or structural abnormalities that are treatable at the time of patient evaluation and b) comprehensive lifestyle interventions, especially weight-loss interventions, which are associated with improvements in OSA severity, cardiometabolic comorbidities, and quality of life. In long-term management, attention should be paid to the clinical changes related to a potential reoccurrence of OSA symptoms and it is also necessary to monitor throughout the follow up how the main associated comorbidities evolve.

Ficheros en este ítem:
Vista previa
Fichero
s40248-019-0186-3.pdf
Descripción
Tamaño
919.87 kB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.